Omega Therapeutics (NASDAQ:OMGA) Stock Rating Reaffirmed by Chardan Capital

Omega Therapeutics (NASDAQ:OMGA)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a note issued to investors on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock. Chardan Capital’s target price indicates a potential upside of 226.34% from the stock’s current price.

A number of other brokerages also recently commented on OMGA. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Omega Therapeutics in a research note on Tuesday, April 30th. Wedbush restated an “outperform” rating and set a $12.00 price target on shares of Omega Therapeutics in a research report on Monday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $9.00 price objective (down from $10.00) on shares of Omega Therapeutics in a research report on Wednesday, April 3rd.

Omega Therapeutics Trading Down 0.5 %

Omega Therapeutics stock opened at $2.15 on Tuesday. Omega Therapeutics has a 1 year low of $1.30 and a 1 year high of $10.09. The firm’s 50-day moving average is $3.11 and its 200-day moving average is $2.98. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.35 and a current ratio of 3.35. The company has a market cap of $118.30 million, a P/E ratio of -1.19 and a beta of 1.99.

Omega Therapeutics (NASDAQ:OMGA) last issued its earnings results on Thursday, March 28th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. The firm had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $0.93 million. Omega Therapeutics had a negative net margin of 3,147.92% and a negative return on equity of 110.41%. On average, equities analysts expect that Omega Therapeutics will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OMGA. Etfidea LLC acquired a new position in shares of Omega Therapeutics during the fourth quarter valued at $39,000. Murphy Pohlad Asset Management LLC bought a new position in Omega Therapeutics in the 4th quarter valued at about $50,000. Finally, 683 Capital Management LLC grew its position in Omega Therapeutics by 7.0% in the 3rd quarter. 683 Capital Management LLC now owns 508,242 shares of the company’s stock valued at $1,093,000 after buying an additional 33,242 shares in the last quarter. Institutional investors and hedge funds own 97.47% of the company’s stock.

Omega Therapeutics Company Profile

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.